Display Settings:

Format

Send to:

Choose Destination

    Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2732-6.

    H-7 effect on outflow facility after trabecular obstruction following long-term echothiophate treatment in monkeys.

    Gabelt BT, Hennes EA, Seeman JL, Tian B, Kaufman PL.

    Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, 53792, USA.

    PURPOSE: To determine whether H-7 can enhance outflow facility after trabecular meshwork obstruction by extracellular material that accumulates after long-term treatment of monkeys with the cholinesterase inhibitor echothiophate iodide (ECHO). METHODS: Cynomolgus monkeys were treated topically with 150 microg ECHO in one (n = 4 eyes) or both (n = 8 eyes) eyes for up to 48 weeks. Accommodation response to topical pilocarpine was monitored periodically. Outflow facility response to H-7 was measured by two-level constant pressure perfusion on three or four different occasions after intraocular pressure was elevated for 12 to 18 weeks. RESULTS: Long-term treatment with ECHO decreased the accommodative response to pilocarpine and increased intraocular pressure, as has been reported. Baseline outflow facility was decreased by 46% +/- 7% (n = 12, P < 0.001). H-7 partially restored baseline outflow facility measured during subsequent perfusions while ECHO treatment was continued. Concurrent H-7 enhanced outflow facility by 73% +/- 18% (n = 12, P < 0.005) beyond the same-day baseline in ECHO-treated eyes. Cessation of ECHO treatment further restored baseline outflow facility, and the outflow facility response to H-7. CONCLUSIONS: H-7 can enhance OF in the presence of trabecular obstruction produced by long-term ECHO treatment. This suggests that H-7 may be useful in treating glaucoma, even in the presence of accumulated plaque material that has been described previously.

    PMID: 15277498 [PubMed - indexed for MEDLINE]

    LinkOut - more resources

    Full Text Sources:

    Other Literature Sources:

    Supplemental Content

    Click here to read

    Patient drug information

    • Pilocarpine (Salagen®)

      Pilocarpine is used to treat dry mouth caused by radiotherapy in people with head and neck cancer and to treat dry mouth in people with Sjogren's syndrome (a condition that affects the immune system and causes dryness of...

    • Pilocarpine Ophthalmic (Isopto® Carpine, Pilopine HS®)

      Pilocarpine is used to treat glaucoma, a condition in which increased pressure in the eye can lead to gradual loss of vision. Pilocarpine relieves the symptoms of glaucoma.